Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Business

Biotech, pharma, and money in science

Adam's Take

Behold the power of magical thinking: How a tiny lung cancer study sent Spectrum’s stock soaring

By Adam Feuerstein

Biotech

FDA approves a game-changing treatment for blood cancer

By Damian Garde

advertisement

Business

CRISPR patent agreement seeks to expand use in crops

By Sharon Begley

advertisement

Pharmalot

Congress isn’t acting to curb drug prices, so states are stepping up. Here’s how

By Ed Silverman

Biotech

Ignyta drug targeting rare lung cancer shows early promise, even when tumors spread to brain

By Adam Feuerstein

Politics

Why do we need drug rebates, anyway? A top lawmaker wants to know

By Ike Swetlitz

Pharmalot

Judge invalidates Allergan patents and criticizes deal with the Mohawks

By Ed Silverman

advertisement

Adam's Take

Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain

By Adam Feuerstein

advertisement

Biotech

After a unanimous panel vote, will Spark’s novel gene therapy be a $1 million drug?

By Adam Feuerstein

In the Lab

‘The Silk Road’: How do you take technology out of the lab and into the world?

By Eric Boodman

Adam's Take

MannKind raises new cash to prop up a sinking inhaled insulin product

By Adam Feuerstein

Hospitals

STAT List: These 10 cities had the biggest jumps in hospital jobs

By Andrew Joseph

Biotech

Spark’s novel gene therapy for blindness is racing to a historic date with the FDA

By Adam Feuerstein

Adam's Take

How a whole lot of hype sent Endocyte’s stock soaring for no good reason

By Adam Feuerstein

Health

A drug with the startling power to mute defective genes raises hopes for a new class of therapies — but hurdles abound

By Meghana Keshavan

Pharma

Cigna says it won’t cover OxyContin prescriptions through employer plans

Adam's Take

Catabasis conjures a stock gain from a failed Duchenne study, assisted by a frothy biotech market

By Adam Feuerstein

Biotech

Amicus’s new approach to Pompe disease shows strong results in improving muscle function

By Adam Feuerstein

Business

The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter

By Adam Feuerstein

Pharma

5 ways pharma is misleading the public on the cost of prescription drugs

By Jay Hancock — Kaiser Health News

Biotech

Zogenix drug cuts seizure rate in severe epilepsy, sending stock skyrocketing

By Adam Feuerstein

Biotech

FDA panel votes no on PTC’s Duchenne muscular dystrophy drug

By Adam Feuerstein

Business

Q&A: Biotech analysts explain which CEOs know their stuff & why pharma should be wary of a friendly FDA

By Adam Feuerstein and Damian Garde

Hospitals

Not even the mattress pads were spared: An inside look at a top hospital’s struggle to cut costs

By Ron Winslow

Pharma

PhRMA CEO announces support for limiting opioid prescriptions

By Andrew Joseph

Biotech

Axovant failed. Now what? A collection of takes hot and cold

By Damian Garde and Adam Feuerstein

Biotech

FDA rips into PTC’s Duchenne muscular dystrophy drug as advisory panel looms

By Adam Feuerstein

Biotech

Another Alzheimer’s failure: Axovant’s drug flops in late-stage trial

By Damian Garde

Biotech

Q&A: How biotech analysts navigate fickle markets, pushy investors, and ‘vindictive’ CEOs

By Adam Feuerstein and Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Leave this field empty if you're human:

Sign up for our morning rounds newsletter

Leave this field empty if you're human:

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
STAT Wunderkinds
Awards for STAT
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X